Siglec-8 as a Drugable Target to Treat Eosinophil and Mast Cell-Associated Conditions

Pharmacology and Therapeutics - United Kingdom
doi 10.1016/j.pharmthera.2012.06.005
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Elsevier BV

Related search

Developmental, Malignancy-Related, and Cross-Species Analysis of Eosinophil, Mast Cell, and Basophil Siglec-8 Expression

Journal of Clinical Immunology
AllergyImmunology
2011English

Siglec-8 on Human Eosinophils and Mast Cells, and Siglec-F on Murine Eosinophils, Are Functionally Related Inhibitory Receptors

Clinical and Experimental Allergy
AllergyImmunology
2009English

Study of Mast Cell and Eosinophil Count in Surgically Resected Appendix

Tropical Journal of Pathology and Microbiology
2019English

Siglec-8 Engagement Selectively Inhibits Allergen-Dependent Degranulation of Human Skin Mast Cells in Vitro

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Systemic Mastocytosis With Associated Clonal Hematological Non-Mast Cell Lineage Disorder (MDS-RCMD): A Difficult Disease to Diagnose and Treat

Indian Journal of Hematology and Blood Transfusion
Hematology
2015English

Identification of Bromodomain-Containing Protein-4 as a Novel Marker and Epigenetic Target in Mast Cell Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2015English

Histone Deacetylase 8 as a Novel Therapeutic Target in Oral Squamous Cell Carcinoma

Oncology Reports
MedicineCancer ResearchOncology
2016English

Interleukin-33 as a Potential Therapeutic Target for Interstitial Cystitis: New Perspectives on Mast Cell Regulation

International Neurourology Journal
NeurologyUrology
2015English

Treat-To-Target Bei Gicht Unerlässlich

CME
Family Practice
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy